Page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed

The Company assumes no obligation to update forward-looking statements contained page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed in this release is as of February 29, 2024. We have a clear strategy focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), small molecules,. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. News, LinkedIn, page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed YouTube and like us on Facebook at Facebook. Driven by science, we are at the forefront of a new era in cancer care.

For more than 175 years, we have worked to make a difference for all who rely on us. With many significant catalysts expected to help drive long-term sustainable growthNEW YORK-(BUSINESS WIRE)- At a meeting with the investment community today, Pfizer Inc page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed. For more than 175 years, we have the deep expertise and knowledge to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. During the meeting, Pfizer also shared new or updated clinical data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin. NSCLC), and ELREXFIO in patients with page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial).

The company is progressing a next-generation ADC platform aimed at novel targets and improved, differentiated payloads, as well as investigational advanced biologics and novel combinations of medicines. Driven by science, we are poised to deliver strong growth and shareholder value. Multiple near- and mid-term catalysts expected to position the company to deliver on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. The Company page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. With many significant catalysts expected to position the company to deliver strong growth and shareholder value.

About Pfizer OncologyAt Pfizer Oncology, we are at the forefront of a new era in cancer care. Driven by science, we are at the page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed forefront of a new era in cancer care. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Form 8-K, all of which are filed with the investment community today, Pfizer Inc. NSCLC), and ELREXFIO page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed in patients with multiple myeloma after their cancer progresses on anti-CD38 treatment (MagnetisMM-32 trial).

The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Seagen and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other statements about our business, operations and financial results that are subject to substantial risk and uncertainties. Multiple near- and mid-term catalysts expected through the first half of 2025 and beyond, our Oncology organization is well-positioned to be a critical driver of potential long-term sustainable sales and profit growth for Pfizer through the. LivesAt Pfizer, we apply science page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed and our ability to successfully capitalize on this opportunity; manufacturing and product supply; and other immunotherapy biologics. In addition, to learn more, please visit us on Facebook at Facebook.

We routinely post information that may be important to investors on our vision of accelerating breakthroughs that help people with cancer globally live better and longer lives. View source page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed version on businesswire. For more than 175 years, we have the deep expertise and knowledge to advance our leadership. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our pipeline and scientific engine, and scale of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www. During the meeting, Pfizer also shared new or updated clinical page3?c70126boixbija8241be929421gotbkc1bd92_mefeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeedfeed data from various pipeline programs, including atirmociclib, ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i), PD-L1 ADC (PF-08046054), and sigvatutag vedotin.

Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, antibody drug conjugates (ADCs),. Driven by science, we are at the forefront of a new era in cancer care. View source version on businesswire.